Screener
Arbutus Biopharma Corporation ABUS Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $19.17M-48.8% | $23.71M-36.1% | $18.01M-50.4% | $22.41M-29.6% | $37.41M-40.4% | ||
| $73.45M+21.1% | $71.52M-5.4% | $73.46M-14.9% | $71.29M-25.7% | $60.68M-23.4% | ||
| $179.37M+17,400% | $178.74M+15,022% | $0-100% | $905K-43.7% | $1.03M-42.0% | ||
| $273.88M+166% | $277.01M+137% | $94.46M-25.8% | $97.44M-26.6% | $103.12M-30.4% | ||
| $10K-93.2% | $22K-86.9% | $32K-99.0% | $137K-96.1% | $148K-96.4% | ||
| $274.03M+165% | $277.16M+137% | $94.62M-28.2% | $97.71M-30.4% | $103.27M-35.5% | ||
| $373K-71.8% | $1.46M-34.7% | $1.17M-49.4% | $1.01M-56.3% | $1.32M-50.2% | ||
| $3.36M-33.0% | $5.11M-73.7% | $6.01M-61.5% | $5.18M-72.6% | $5.02M-77.8% | ||
| $0— | $0— | —— | $0— | $0— | ||
| $15.29M-24.6% | $16.99M-55.1% | $18.04M-47.5% | $20.31M-39.5% | $20.29M-46.0% | ||
| $1.45B+2.2% | $1.44B+2.0% | $1.42B+0.8% | $1.42B+0.8% | $1.42B+1.0% | ||
| -$1.22B+11.2% | -$1.21B+11.7% | -$1.38B-2.5% | -$1.38B-3.2% | -$1.37B-4.1% | ||
| $258.73M+212% | $260.18M+229% | $76.58M-21.4% | $77.4M-27.6% | $82.98M-32.2% | ||
| $274.03M+165% | $277.16M+137% | $94.62M-28.2% | $97.71M-30.4% | $103.27M-35.5% |
FAQ
- What are Arbutus Biopharma Corporation's total assets?
- Arbutus Biopharma Corporation (ABUS) holds $274.0M in total assets, up 165.4% year over year.
- How much debt does Arbutus Biopharma Corporation have?
- Arbutus Biopharma Corporation carries $514.0K in total debt against $258.7M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Arbutus Biopharma Corporation have?
- Arbutus Biopharma Corporation holds $19.2M in cash and equivalents.
- Can Arbutus Biopharma Corporation cover its short-term obligations?
- Its current ratio is 81.42 — current assets exceed current liabilities.
- Where does Arbutus Biopharma Corporation's balance sheet data come from?
- Every line is extracted from Arbutus Biopharma Corporation's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
